Coherus Oncology, Inc. CHRS R2KR3KPHARMA
Company Overview
Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype (IgG1) monoclonal antibody targeting interleukin IL-27. It also develops CHS-114, an investigational human afucosylated IgG1 monoclonal antibody, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME) patients with head and neck squamous cell carcinoma. It has a collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab; agreements with Surface and Adimab LLC; license agreements with Bioeq AG and Genentech, Inc. and Surface and Vaccinex, Inc.; and out-licensing agreement with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. It also has a clinical collaboration agreement with Zumutor Biologics Inc. for the development of LOQTORZI with ZM0008 as a treatment for cancer patients. The company was formerly known as Coherus BioSciences, Inc. and changed its name to Coherus Oncology, Inc. in May 2025. The company was incorporated in 2010 and is based in Redwood City, California.
Why Investors Should Care
Revenue has grown at a 26.9% CAGR over the past five years.
Recent Developments
- Dec 2025 Revenue of $42.17M (+59.8% YoY); net profit $168.02M.
- Trailing 12 Months Year-on-year growth — revenue +39.5%, earnings +489.4%.
- 5-Year Trend Long-term compounding — revenue CAGR 26.9%, profit CAGR 4.9%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 26.93% |
| 1 Year: | 39.50% |
Compounded Profit Growth
| 5 Years: | 4.91% |
| 1 Year: | 489.41% |
Stock Price Performance
| 1 Year: | +42.14% |
| 6 Months: | -21.98% |
| 3 Months: | -2.07% |
| 1 Month: | +12.25% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMABelow
- RSI (14)53.70 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 26.9% over 5 years.
CONS
- Trading 43.4% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | CHRS Coherus Oncology, Inc. R2KR3KPHARMA | 1.42 | -1.15 | $219.03M | 0.00% | - | - | 26.93% | 4.91% |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,149.36 | 38.57 | $1.02T | 0.58% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 275.23 | 31.97 | $663.28B | 2.09% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 256.46 | 72.45 | $453.19B | 2.84% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 150.33 | 120.26 | $371.29B | 2.65% | - | 34.70% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 397.14 | 25.54 | $356.47B | 2.33% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 159.99 | 24.20 | $304.10B | 3.03% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 162.70 | 24.36 | $252.33B | 1.98% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | AMGN Amgen Inc. NDXSPXR3KPHARMA | 437.23 | 27.14 | $235.98B | 2.49% | 13.95% | 91.47% | 5.51% | 5.55% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2015 | Jun 2015 | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | 161.00K | 1.40M | 0 | 0 | 0 | 0 | 0 | 0 | 37.10M | 83.43M | 111.68M | 123.86M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 34.87M | 82.83M | 105.24M | 116.05M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Income | -36.75M | -58.90M | -71.22M | - | -64.35M | -62.74M | 84.62M | - | -72.42M | -56.64M | -56.62M | - | -42.03M | -44.91M | -56.97M | - | -16.60M | 27.49M | 51.84M | - | 40.87M | 65.31M | 33.72M | -167.36M | -24.16M | -32.79M | -80.92M | -44.01M | -80.45M | -67.75M | -34.54M | -32.01M | -67.79M | -39.63M | -46.86M | -45.44M | -45.49M | -44.33M | -36.15M | -32.33M |
| Net Income | -40.73M | -58.81M | -71.33M | -52.39M | -65.39M | -69.97M | 83.94M | -75.92M | -74.78M | -55.34M | -58.99M | -49.07M | -44.30M | -43.64M | -58.81M | -62.60M | -20.00M | 23.57M | 47.04M | - | 35.57M | 59.03M | 27.93M | -172.95M | -29.90M | -38.53M | -96.08M | -50.15M | -86.65M | -75.73M | -42.87M | -39.64M | 102.88M | -12.92M | -10.75M | -56.57M | 297.77M | -35.53M | -38.33M | -20.63M |
| Diluted EPS | - | - | -1.86 | - | -1.67 | -1.72 | 1.67 | -1.71 | - | - | -1.09 | - | - | -0.68 | -0.87 | - | -0.29 | 0.32 | 0.63 | 0.53 | 0.48 | 0.70 | 0.33 | -2.37 | -0.40 | -0.49 | -1.24 | -0.65 | -1.11 | -0.96 | -0.49 | -0.41 | 0.91 | -0.11 | -0.09 | -0.49 | 2.57 | -0.31 | -0.28 | -0.13 |
| R&D Expense | 36.47M | 56.94M | 68.22M | - | 65.31M | 65.54M | 64.57M | - | 53.77M | 34.50M | 42.63M | - | 25.45M | 26.52M | 31.60M | - | 18.79M | 18.88M | 21.57M | - | 33.11M | 26.17M | 38.85M | 203.49M | 54.77M | 54.09M | 82.92M | 41.61M | 45.81M | 34.15M | 23.27M | 25.65M | 28.42M | 20.60M | 22.05M | 24.36M | 26.31M | 27.25M | 21.54M | 21.44M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.90M | 2.75M | 31.11M | 30.04M | 189.48M | 1.56M | 0 | 356.07M | 475.82M | 326.55M | 211.04M | 257.24M | 26.39M | 42.17M |
| Operating Income | -38.52M | -35.99M | -64.68M | -219.07M | -115.93M | -232.14M | -204.42M | 107.77M | 156.32M | -263.86M | -256.88M | -203.20M | -199.65M | -181.13M |
| Net Income | -33.02M | -53.63M | -87.13M | -223.26M | -127.34M | -238.17M | -209.34M | 89.83M | 132.24M | -287.10M | -291.75M | -237.89M | 28.51M | 168.02M |
| Diluted EPS | - | - | - | - | - | -4.48 | -3.22 | 1.23 | 1.62 | -3.81 | -3.76 | -2.53 | 0.25 | 1.43 |
| R&D Expense | 34.89M | 31.28M | 78.22M | 213.06M | 254.44M | 162.39M | 110.24M | 94.19M | 142.76M | 363.11M | 199.36M | 109.44M | 91.83M | 108.89M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 47.45M | 187.22M | 212.38M | 178.49M | 162.61M | 99.47M | 408.93M | 841.65M | - | 480.85M | 629.60M | 448.53M | 258.34M |
| Current Assets | - | - | - | - | - | - | - | - | - | - | - | 381.23M | 475.63M | 341.58M | 206.71M |
| Cash & Equivalents | 7.68M | 14.55M | 39.55M | 150.39M | 158.23M | 124.95M | 126.91M | 72.36M | 177.67M | 541.16M | - | 63.55M | 102.89M | 125.99M | 88.88M |
| Inventory | - | - | - | - | - | - | - | - | - | - | - | 38.79M | 62.60M | 4.21M | 3.17M |
| Receivables | - | - | - | - | - | - | - | - | - | - | - | 109.96M | 260.52M | 111.32M | 17.82M |
| Total Liabilities | - | - | 89.83M | 120.46M | 219.31M | 159.13M | 132.08M | 138.06M | 303.71M | 560.67M | - | 618.26M | 823.03M | 580.52M | 197.33M |
| Current Liabilities | - | - | 53.70M | 51.78M | 106.02M | 56.38M | 28.39M | 33.26M | 114.97M | 145.65M | - | 138.69M | 331.77M | 282.98M | 141.88M |
| Long Term Debt | - | - | - | - | - | - | - | - | - | - | - | 471.06M | 473.37M | 264.93M | 37.05M |
| Total Debt | - | - | - | - | - | - | - | - | - | - | - | 480.42M | 480.84M | 269.90M | 40.34M |
| Total Equity | -2.31M | -45.50M | -97.08M | 66.80M | -6.21M | 20.53M | 30.54M | -38.59M | 105.21M | 280.97M | - | -137.42M | -193.43M | -131.99M | 61.01M |
| Shares Outstanding | - | - | - | - | - | - | - | - | - | - | - | 78.85M | 112.22M | 115.61M | 121.15M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | -252.54M | -200.29M | -159.27M | 28.36M | 154.15M | -37.43M | -241.12M | -174.88M | -20.44M | -138.51M |
| Investing Cash Flow | - | - | - | - | -6.51M | -4.42M | -1.19M | -12.73M | -14.40M | -138.41M | -166.85M | 144.64M | 230.32M | 375.09M |
| Financing Cash Flow | - | - | - | - | 226.18M | 206.79M | 105.42M | 89.37M | 223.95M | 51.88M | 54.33M | 69.60M | -186.97M | -273.70M |
| Capital Expenditure | -1.78M | -373.00K | -2.85M | -6.16M | -6.51M | -4.57M | -789.00K | -1.82M | -7.23M | -1.29M | -2.04M | -286.00K | - | - |
| Free Cash Flow | - | - | - | - | -259.06M | -204.86M | -160.06M | 26.53M | 146.91M | -38.72M | -243.16M | -175.17M | - | - |
| Share Buybacks | - | - | 2.00K | - | - | - | - | - | - | - | - | - | - | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | -2,028.3% | -1,308.4% | -207.9% | -729.2% | -61.2% | -14,918.8% | - | 30.3% | 32.9% | -80.8% | -121.7% | -79.0% | -756.6% | -429.5% |
| Net Margin % | -1,738.7% | -1,949.7% | -280.1% | -743.2% | -67.2% | -15,306.6% | - | 25.2% | 27.8% | -87.9% | -138.2% | -92.5% | 108.0% | 398.4% |
| ROE % | 72.6% | 55.2% | -130.4% | 3,596.9% | -620.3% | -780.0% | 542.5% | 85.4% | 47.1% | - | 212.3% | 123.0% | -21.6% | 275.4% |
| ROCE % | - | 575.5% | -47.8% | -206.0% | -94.9% | -173.0% | -308.8% | 36.7% | 22.5% | - | -75.1% | -68.2% | -120.6% | -155.5% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Timothy G. Youngquist 2020 Irrevocable Trust | 8.45% | 13.05M | $18.40M |
| 2 | Blackrock Inc. | 7.77% | 12.00M | $16.92M |
| 3 | Vanguard Capital Management LLC | 3.85% | 5.95M | $8.39M |
| 4 | Geode Capital Management, LLC | 2.39% | 3.69M | $5.20M |
| 5 | Samsara BioCapital, LLC | 2.22% | 3.43M | $4.83M |
| 6 | Kohlberg Kravis Roberts & Co. L.P. | 1.97% | 3.04M | $4.28M |
| 7 | State Street Corporation | 1.54% | 2.38M | $3.36M |
| 8 | Two Sigma Investments, LP | 1.46% | 2.26M | $3.19M |
| 9 | CM Management, LLC | 1.36% | 2.10M | $2.96M |
| 10 | C WorldWide Group Holding A/S | 1.25% | 1.93M | $2.72M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for CHRS
Coherus will give eligible holders rights to cash from former assets—but they may expire unpaid - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiwAFBVV95cUxNOWVtTWotUVVJSk05Z0E1bVpmY1E3eUtBaFdDaDU2TGVvUHl3RkFSY05oV21HXzJ4d1pJcmswX1ZLX3ZKempXa3VHMWZXMkNubTdiMWJOaDg0Q2lfTDRYSXhQd0JuYl9tTU45S1BHOXRKbUJpN1FTWVhxdFdBanVXbldJalpjbGtfeVlvWD…
Coherus Oncology (CHRS) Reports Q2 Loss, Misses Revenue Estimates - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMingFBVV95cUxQRDNjQ3Znb1VsbzJTYmhtLWp3NEEzSmtPcFZVbE5HWjBONExBRW1wdHZoaUVZekJpTVI0SHFoWUoxQ1JuQzlHOUFWa2lRSDN2M2w4WEZpYzZxWmloeC1iTHF5VnZxZmNZeDY2MVVkd0d1NS16ZU0xUkJzeHZvQXNnTEhQTWFrODRKNERkVD…
CHRS - Finviz
<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTE5yMXNjMUFEVnVtUnVsZXJBSTNkMTFhOVBKRmZUYjBPSm14eEFBTFVhMW1sLUxEVmhPeTBWSHpGTFY3NEI2cGc?oc=5" target="_blank">CHRS</a> <font color="#6f6f6f">Finviz</font>…
CHRS Forecast — Price Target — Prediction for 2027 - TradingView
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTE1MS09RZFJNRW9BdzdGUWRWYVNjbHVZWFRXNnp4MlJBOGRZcmxIMXhxSF9fSjhHRmU4OVFRQ3VQM0xmZVZycWtkdzc1WkczMU5felFJNGVqMDM1MGpSV1VDQ2oxWndaVWViWW4yRXhsRTBKUDVYc1hib1Rn?oc=5" target="_blank">CHR…
Coherus Oncology: The Catalyst Rich Period Is Here (NASDAQ:CHRS) - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMilAFBVV95cUxOaWI2NjVtdEplWE04dlZZTTJFVWwzU2ptaFRmX09lVDQyUFNIZ0lqQUtYakUwVGNpeFM3MWl5MWZCM01MV1BSS0x0dVpVa2U1WWJzZ1ZDRFRJWU91M19qSy1sMjVMdExGSUlYOU9HeFRMazJZZXBVekpfTmUwbVBpSHdNbmJSbUV0Sm9vSW…
Coherus Oncology Announces Special Dividend of Contingent Value Rights Tied to Legacy Biosimilar Asset Sales - quiverquant.com
<a href="https://news.google.com/rss/articles/CBMi2AFBVV95cUxPQUFmQU42WlkzaEhZMC1vLXEtTVRsNHNxanI5dk04eTZ2OWtfaFFnMkFQTGl3YnFSZURDd3dwbW5mbVlxLTBpaWNxSXV5bG9EMXEzSldqOEF0X2JQd1pFcjFpTU4yYWM0Z2huR3RDRi1oRUVYbHpJbFRvNUUwOURiVVN2UDRBZ1R3SVYwUn…
CHRS — Frequently Asked Questions
What is the current share price of Coherus Oncology, Inc. (CHRS)?
As of 2026-09-07 16:24 PDT, Coherus Oncology, Inc. (CHRS) trades at $1.42 on NasdaqGM. Its 52-week range is $1.00 to $2.51.
What is the market capitalisation of CHRS?
Coherus Oncology, Inc. (CHRS) has a market capitalisation of $219.03M on NasdaqGM.
What is the P/E ratio of CHRS?
CHRS trades at a trailing price-to-earnings (P/E) ratio of -1.15. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 2.49.
Is CHRS a good stock to buy?
This page provides a data-driven analysis of Coherus Oncology, Inc. (CHRS), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.